U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

peginterferon alfa-2a response - Efficacy

MedGen UID:
1003613
•Concept ID:
CN322747
•
Sign or Symptom

Professional guidelines

PubMed

Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.
Huang Y, Li MH, Hou M, Xie Y
Hepatobiliary Pancreat Dis Int 2017 Oct 15;16(5):470-479. doi: 10.1016/S1499-3872(17)60044-4. PMID: 28992878
Hepatitis B viral factors and treatment responses in chronic hepatitis B.
Lin CL, Kao JH
J Formos Med Assoc 2013 Jun;112(6):302-11. Epub 2013 Mar 17 doi: 10.1016/j.jfma.2013.02.001. PMID: 23787007
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
Noureddin M, Ghany MG
Gastroenterol Clin North Am 2010 Sep;39(3):649-58. doi: 10.1016/j.gtc.2010.08.008. PMID: 20951922Free PMC Article

Recent clinical studies

Etiology

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C.
Yu J, Xu D
Contrast Media Mol Imaging 2022;2022:7623832. Epub 2022 Sep 28 doi: 10.1155/2022/7623832. PMID: 36247853Free PMC Article
The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.
He Y, Zhou Y, Wang H, Peng X, Chang Y, Hu P, Ren H, Xu H
BMC Pediatr 2022 Jul 20;22(1):426. doi: 10.1186/s12887-022-03482-0. PMID: 35854256Free PMC Article
Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L
Clin Res Hepatol Gastroenterol 2014 Sep;38(4):440-50. Epub 2013 Oct 28 doi: 10.1016/j.clinre.2013.08.013. PMID: 24176812
Telaprevir user's guide.
Liapakis AM, Jacobson I
Liver Int 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. PMID: 22212567
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D, Jones J, Baxter L, Shepherd J
Health Technol Assess 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170. PMID: 21473834Free PMC Article

Diagnosis

Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.
Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network
Hepatology 2019 Jun;69(6):2338-2348. Epub 2019 Mar 14 doi: 10.1002/hep.30417. PMID: 30549279Free PMC Article
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.
Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, Fischler B, Kelly D
J Hepatol 2010 Jun;52(6):827-31. Epub 2010 Mar 15 doi: 10.1016/j.jhep.2010.01.028. PMID: 20400194
Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
Caruntu FA, Streinu-Cercel A, Gheorghe LS, Grigorescu M, Sporea I, Stanciu C, Andronescu D, Voinea F, Diculescu M, Oproiu A, Voiosu R
J Gastrointestin Liver Dis 2009 Dec;18(4):425-31. PMID: 20076814
New and emerging treatment of chronic hepatitis B.
Keeffe EB, Marcellin P
Clin Gastroenterol Hepatol 2007 Mar;5(3):285-94. Epub 2007 Jan 9 doi: 10.1016/j.cgh.2006.09.036. PMID: 17218162
Improving anti-hepatitis C virus therapy.
Pol S, Mallet VO
Expert Opin Biol Ther 2006 Sep;6(9):923-33. doi: 10.1517/14712598.6.9.923. PMID: 16918259

Therapy

Interferon Alpha 2a and 2b in Ophthalmology: A Review.
Lewczuk N, Zdebik A, Bogusławska J
J Interferon Cytokine Res 2019 May;39(5):259-272. Epub 2019 Apr 5 doi: 10.1089/jir.2018.0125. PMID: 30950678
Peginterferon alfa-2a for the treatment of chronic hepatitis C in the era of direct-acting antivirals.
Huang Y, Li MH, Hou M, Xie Y
Hepatobiliary Pancreat Dis Int 2017 Oct 15;16(5):470-479. doi: 10.1016/S1499-3872(17)60044-4. PMID: 28992878
Telaprevir user's guide.
Liapakis AM, Jacobson I
Liver Int 2012 Feb;32 Suppl 1:17-25. doi: 10.1111/j.1478-3231.2011.02708.x. PMID: 22212567
Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C.
Noureddin M, Ghany MG
Gastroenterol Clin North Am 2010 Sep;39(3):649-58. doi: 10.1016/j.gtc.2010.08.008. PMID: 20951922Free PMC Article
Peginterferon alfa-2a: a review of approved and investigational uses.
Matthews SJ, McCoy C
Clin Ther 2004 Jul;26(7):991-1025. doi: 10.1016/s0149-2918(04)90173-7. PMID: 15336466

Prognosis

The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.
He Y, Zhou Y, Wang H, Peng X, Chang Y, Hu P, Ren H, Xu H
BMC Pediatr 2022 Jul 20;22(1):426. doi: 10.1186/s12887-022-03482-0. PMID: 35854256Free PMC Article
Interferon Alpha 2a and 2b in Ophthalmology: A Review.
Lewczuk N, Zdebik A, Bogusławska J
J Interferon Cytokine Res 2019 May;39(5):259-272. Epub 2019 Apr 5 doi: 10.1089/jir.2018.0125. PMID: 30950678
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D, Jones J, Baxter L, Shepherd J
Health Technol Assess 2011 Apr;15(17):i-xii, 1-210. doi: 10.3310/hta15170. PMID: 21473834Free PMC Article
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents.
Sokal EM, Bourgois A, Stéphenne X, Silveira T, Porta G, Gardovska D, Fischler B, Kelly D
J Hepatol 2010 Jun;52(6):827-31. Epub 2010 Mar 15 doi: 10.1016/j.jhep.2010.01.028. PMID: 20400194
Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.
Rajender Reddy K, Modi MW, Pedder S
Adv Drug Deliv Rev 2002 Jun 17;54(4):571-86. doi: 10.1016/s0169-409x(02)00028-5. PMID: 12052715

Clinical prediction guides

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C.
Yu J, Xu D
Contrast Media Mol Imaging 2022;2022:7623832. Epub 2022 Sep 28 doi: 10.1155/2022/7623832. PMID: 36247853Free PMC Article
The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B.
He Y, Zhou Y, Wang H, Peng X, Chang Y, Hu P, Ren H, Xu H
BMC Pediatr 2022 Jul 20;22(1):426. doi: 10.1186/s12887-022-03482-0. PMID: 35854256Free PMC Article
Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L
Clin Res Hepatol Gastroenterol 2014 Sep;38(4):440-50. Epub 2013 Oct 28 doi: 10.1016/j.clinre.2013.08.013. PMID: 24176812
Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b.
Foster GR
Drugs 2010;70(2):147-65. doi: 10.2165/11531990-000000000-00000. PMID: 20108989
Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.
Rajender Reddy K, Modi MW, Pedder S
Adv Drug Deliv Rev 2002 Jun 17;54(4):571-86. doi: 10.1016/s0169-409x(02)00028-5. PMID: 12052715

Recent systematic reviews

Antiviral therapy in chronic hepatitis E: a systematic review.
Peters van Ton AM, Gevers TJ, Drenth JP
J Viral Hepat 2015 Dec;22(12):965-73. Epub 2015 Mar 11 doi: 10.1111/jvh.12403. PMID: 25760481
Efficacy and safety of peginterferon plus ribavirin for patients aged ≥ 65 years with chronic hepatitis C: a systematic review and meta-analysis.
Yang Z, Zhuang L, Yang L, Liu C, Lu Y, Xu Q, Chen X, Chen L
Clin Res Hepatol Gastroenterol 2014 Sep;38(4):440-50. Epub 2013 Oct 28 doi: 10.1016/j.clinre.2013.08.013. PMID: 24176812
Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis.
Basso M, Parisi SG, Mengoli C, Gentilini V, Menegotto N, Monticelli J, Nicolè S, Cruciani M, Palù G
HIV Clin Trials 2013 Jul-Aug;14(4):127-39. doi: 10.1310/hct1404-127. PMID: 23924585
Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.
Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ
Clin Infect Dis 2013 Apr;56(7):961-7. Epub 2012 Dec 12 doi: 10.1093/cid/cis1031. PMID: 23243171
Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials.
Singal AK, Jampana SC, Anand BS
Dig Dis Sci 2011 Aug;56(8):2221-6. Epub 2011 Jun 4 doi: 10.1007/s10620-011-1765-0. PMID: 21643737

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...